IRIS

Sfoglia per Rivista  

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mostrati risultati da 9 a 28 di 32
Titolo Data di pubblicazione Autore(i) File
CYCLOPHOSPHAMIDE VERSUS IFOSFAMIDE - A RANDOMIZED PHASE-II TRIAL IN ADULT SOFT-TISSUE SARCOMAS 1-gen-1993 Bramwell, Vhc; Mouridsen, Ht; Santoro, A; Blackledge, G; Somers, R; Verweij, J; Dombernowsky, P; Onsrud, M; Thomas, D; Sylvester, R; Vanoosterom, A
Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin 1-gen-1999 Zucchetti, M; Boiardi, A; Silvani, A; Parisi, I; Piccolrovazzi, S; D'Incalci, M
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma 1-gen-2007 Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies 1-gen-2003 Meco, D; Colombo, T; Ubezio, P; Zucchetti, M; Zaffaroni, M; Riccardi, A; Faircloth, G; Jose, J; D'Incalci, M; Riccardi, R
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin) - An example of potential problems for extrapolation of active drug concentrations from in vitro studies 1-gen-2004 Tognon, G; Frapolli, R; Zaffaroni, M; Erba, E; Zucchetti, M; Faircloth, Gt; D'Incalci, M
Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites 1-gen-1998 Ghielmini, M; Colli, E; Bosshard, G; Pennella, G; Geroni, C; Torri, V; D'Incalci, M; Cavalli, F; Sessa, C
IFOSFAMIDE PLUS DOXORUBICIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMA 1-gen-1993 Schutte, J; Mouridsen, Ht; Steward, W; Santoro, A; Vanoosterom, At; Somers, R; Blackledge, G; Verweij, J; Dombernowsky, P; Thomas, D; Sylvester, R
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer 1-gen-2009 Chiarion-Sileni, V; Innocente, R; Cavina, R; Ruol, A; Corti, L; Pigozzo, J; Del Bianco, P; Fumagalli, U; Santoro, A; Ancona, E
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 1-gen-1992 Bianchi, R; Citti, L; Beghetti, R; Romani, L; D'Incalci, M; Puccetti, P; Fioretti, Mc
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma 1-gen-2009 Reni, M; Cereda, S; Balzano, G; Passoni, P; Rognone, A; Zerbi, A; Nicoletti, R; Mazza, E; Arcidiacono, Pg; Di Carlo, V; Villa, E
PERSPECTIVES ON ANTHRACYCLINES PLUS IFOSFAMIDE IN ADVANCED SOFT-TISSUE SARCOMAS 1-gen-1993 Casali, P; Pastorino, U; Azzarelli, A; Bertulli, R; Zucchinelli, P; Devizzi, L; Santoro, A
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 1-gen-2017 Ballerini, A; Moro, F; Nerini, If; Marzo, Cm; Di Clemente, A; Ferrari, M; D'Incalci, M; Biondi, A; Colombini, A; Conter, V; Porcu, L; Cervo, L; Rizzari, C; Zucchetti, M
Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial 1-gen-2016 Krischke, M; Hempel, G; Voller, S; Andre, N; D'Incalci, M; Bisogno, G; Kopcke, W; Borowski, M; Herold, R; Boddy, Av; Boos, J
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph plus acute leukemias 1-gen-2009 Marangon, E; Citterio, M; Sala, F; Barisone, E; Lippi, Aa; Rizzari, C; Biondi, A; D'Incalci, M; Zucchetti, M
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib 1-gen-2013 Zucchetti, M; Bonezzi, K; Frapolli, R; Sala, F; Borsotti, P; Zangarini, M; Cvitkovic, E; Noel, K; Ubezio, P; Giavazzi, R; D'Incalci, M; Taraboletti, G
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma 1-gen-2000 Fumagalli, L; Zucchetti, M; Parisi, I; Viganò, M G; Zecca, B; Careddu, A; D'Incalci, M; Lazzarin, A
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243) 1-gen-1999 Sessa, C; Zucchetti, M; Ghielmini, M; Bauer, J; D'Incalci, M; de Jong, J; Naegele, H; Rossi, S; Pacciarini, Ma; Domenigoni, L; Cavalli, F
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 1-gen-2016 Belli, C; Piemonti, L; D'Incalci, M; Zucchetti, M; Porcu, L; Cappio, S; Doglioni, C; Allavena, P; Ceraulo, D; Maggiora, P; Dugnani, E; Cangi, Mg; Garassini, G; Reni, M
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone 1-gen-2006 Verschoyle, Re; Greaves, P; Cai, H; Arndt, B; Broggini, M; D'Incalci, M; Riccio, E; Doppalapudi, R; Kapetanovic, Im; Steward, Wp; Gescher, Aj
PREOPERATIVE DOXORUBICIN PLUS IFOSFAMIDE IN PRIMARY SOFT-TISSUE SARCOMAS OF THE EXTREMITIES 1-gen-1993 Azzarelli, A; Quagliuolo, V; Casali, P; Fissi, S; Montalto, F; Santoro, A
Mostrati risultati da 9 a 28 di 32
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile